Table 2.
P. falciparum strain(s) | Humanized mice | Applications | References |
---|---|---|---|
NF54 or multiresistant T24 | BXN (Beige/Xid/Nude) | First rodent model for P.falciparum study, to test the novel compounds for the drug development and evaluation of drug responses, vaccine development | (136–138) |
FUP, NF54, 3D7, Dd2 and clinical isolates | SCID (Severe Combined Immunodeficiency) and NOD/SCID | Helpful in in-vivo studies of human malaria parasites and vaccine development | (139–141) |
Mouse-adapted 3D7 | NOD/SCID/β2microglobulin (β2m)−/− | in-vivo experimental drug/exposure-response assay | (142) |
Mouse-adapted 3D7 | NOD/SCID/IL-2 receptor γ chain (IL2Rγ)nullor NSG mice | To check the response against various antimalarial therapeutics | (143, 144) |
Different parasite strains (3D7,UPA and K1) without any prior adaptation | NOD/SCID/IL-2 receptor γ chain (IL2Rγ)null or NSG mice with an additional treatment of clodronate delivered through liposomes | Most comprehensive humanized mouse model allowing to develop the sexual stage parasites besides the asexual-blood stage development | (134, 145) |
NF54, 3D7 | HLA-transgenic mice | Discovery of novel protective malaria antigen and immune responses | (146) |
NF54 | TK/NOG | Used to assess the drug toxicology and metabolism, and P. falciparum infection in transplanted human hepatocytes | (6) |
TK/NOG, thymidine kinase/NOD/Shi-scid/IL-2Rγnull mice; HLA, human leukocytes antigen; 3D7, NF54, PAM, different P. falciparum strain.